TY - CHAP M1 - Book, Section TI - Acneiform Disorders A1 - Usatine, Richard P. A1 - Sabella, Camille A1 - Smith, Mindy Ann A1 - Mayeaux, E.J. A1 - Chumley, Heidi S. A1 - Appachi, Elumalai Y1 - 2015 N1 - T2 - The Color Atlas of Pediatrics AB - References1Purdy S, de Berker D. Acne vulgaris. Clin Evid (Online). 2011 Jan 5;2011. pii:1714.2Smith EV, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews published in 2009- 2010. Clin Exp Dermatol. 2011;36:119–122.20738323[PubMed: ]3Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–663.17276540[PubMed: ]4Shirakawa M, Uramoto K, Harada FA. Treatment of acne conglobata with infliximab. J Am Acad Dermatol. 2006;55:344–346.16844527[PubMed: ]5Grunwald MH, Amichai B. Nodulo-cystic eruption with musculoskeletal pain. J Fam Pract. 2007;56:205–206.17343810[PubMed: ]6AHRQ. Management of Acne. http://www.ahrq.gov/clinic/epcsums/acnesum.htm [serial online]. 2001.7Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439–410.17208334[PubMed: ]8Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4–11.12095066[PubMed: ]9Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003; CD002086.10Maleszka R, Turek-Urasinska K, Oremus M, et al. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study. Skinmed. 2011;9:86–94.21548512[PubMed: ]11Enshaieh S, Jooya A, Siadat AH, Iraji F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol. 2007;73:22–25.17314442[PubMed: ]12Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol. 1993;28:572–579.7681856[PubMed: ]13Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–309.10468806[PubMed: ]14Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9:549–558.20480800[PubMed: ]15Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006;142:605–612.16702498[PubMed: ]16Yeung CK, Shek SY, Bjerring P, et al. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med. 2007;39:1–6.17252567[PubMed: ]17Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol. 2006;54:647–651.16546587[PubMed: ]18Horfelt C, Funk J, Frohm-Nilsson M, et al. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol. 2006;155:608–613.16911289[PubMed: ] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/23 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1114874228 ER -